Company / Net Income
Intellia Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$412.7M
FY2025
5-year range
-$519.0M / -$267.9M
FY2021-FY2025
Trend
+20.5%
vs FY2024
Sector context
#146 of 158
Health Care
What the data says
Among 158 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 8% for net income. Net Income returned to growth in FY2025 after 4 years of decline, reaching -$413M.
Based on SEC 10-K filings.
-$413M in FY2025.
Improved from -$481M to -$413M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 158This company -$412.7M Sector average $458.6M
▼
-190.0% below sector average
Key checks
Key Insights
- In FY2025, net income increased 20.5% year-over-year.
- Ranks #146 out of 158 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$412.7M | +20.5% |
| FY2024 | -$519.0M | -7.9% |
| FY2023 | -$481.2M | -1.5% |
| FY2022 | -$474.2M | -77.0% |
| FY2021 | -$267.9M | -99.6% |
| FY2020 | -$134.2M | +71.7% |
| FY2019 | -$474.2M | -455.6% |
| FY2018 | -$85.3M | -26.4% |
| FY2017 | -$67.5M | -113.5% |
| FY2016 | -$31.6M | -155.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026